Feedback plc (LSE:FDBK), the developer of the Bleepa clinical collaboration platform, has said its cash should last until mid-2027 as it waits for a central NHS decision on wider adoption of its technology. The central question is how the AIM-quoted health technology company is managing its resources while a potentially transformative, but uncertain, national contract remains undecided.
What Feedback does
Feedback develops software for the NHS. Its main product, Bleepa, is described by the company as a collaboration platform designed to improve the quality and productivity of patient pathways. It connects existing digital systems and allows clinicians to work asynchronously, which the company says can reduce unnecessary appointments and geographic barriers. Bleepa is used in pathways run with NHS trusts and partners, including an insomnia pathway delivered in Sussex with Patients Know Best.
The latest trading update
On 14 July 2026, Feedback issued a trading update for the financial year ended 31 May 2026. The company said Revenue was approximately £0.8m, compared with £0.9m in the previous year. It reported cash of £2.7m at the year end, which it described as "ahead of expectations due to faster collections and cost control". The company said it expected its EBITDA loss to be lower than expectations and smaller than in the prior year, and stated that it had "sufficient cash runway through to mid-2027".
On the national opportunity, Feedback said it remained "hopeful of a decision around the calendar year end once NHSE and HM Treasury have concluded their evaluation". It also reported that integration with the NHS e-Referral Service had produced a tenfold increase in the number of GP practices referring into Bleepa, and that it had released version 1.7 of the platform. It cited clinical results indicating that "100% of Breathlessness patients" on a pathway were "diverted away from outpatient appointments", and said the insomnia pathway had been rolled out across Kent, Surrey and Sussex.
No later announcement had been published as at 1 October 2026, and audited results for the year had not yet appeared.
Contracts and recent history
An earlier update on 20 April 2026 explained that a central NHS decision on widescale adoption had been delayed by six to nine months because of internal NHS factors. At that time, Feedback said Queen Victoria Hospital NHS Foundation Trust had extended Bleepa licences for nine months to December 2026, at an annualised contract value of £495,000. Northern Care Alliance NHS Foundation Trust granted an annual extension, while a photocapture contract with Royal Berkshire NHS Foundation Trust was not renewed when its three-year term ended in March 2026.
Taken together, these updates suggest a Business with modest recurring revenue, reliant on a small number of NHS customers, that has reduced costs to preserve cash while it waits for a larger decision.
Risks and points to watch
The main uncertainty is the NHS decision itself. It has already been delayed once, and its timing depends on NHS England and HM Treasury rather than the company. If a national contract is not awarded, or is smaller than hoped, Feedback's revenue base would remain limited. The cash runway to mid-2027 is based on current plans, so a further delay could require new funding, potentially diluting existing shareholders. Contract renewals are also important, given that the Queen Victoria Hospital extension runs only to December 2026. Shareholders will look for the audited results, which should give fuller detail on losses and cash.
Conclusion
Feedback is stretching its cash runway by collecting receivables faster and controlling costs, leaving it with £2.7m at its year end and funding it says lasts to mid-2027. Its prospects depend heavily on an NHS decision it hopes to receive around the end of 2026, which remains outside its control.






Please wait processing your request...